BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Cipla Ltd. is at 10% share while Lupin Ltd., which launched it about a month back, has also ramped up to 4% share.
Incumbents Glaxosmithkline Ltd. (Ventolin) and Teva (Proair) have maintained their prescription volumes while Cipla and Lupin have gained from Perrigo’s exit.
Cipla’s gain has also come from the cannibalisation of Proventil brand and authorised generics’ share, which is down 73% from pre-generic levels.
Sun Pharma Ltd. is consistently building prescription volume in Cequa with a 20% growth so far over its Q2 FY21 weekly exit volume.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR